Evidence map›Paper›PMID 26857832›Full record

ArticleCancer causes & control : CCC2016

Prospective analysis of association between statins and pancreatic cancer risk in the Women's Health Initiative.

Michael S Simon, Pinkal Desai, Robert Wallace, Chunyuan Wu, Barbara V Howard, Lisa W Martin, Nicolas Schlecht, Simin Liu, Allison Jay, Erin S LeBlanc and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer causes & control : CCC, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Review
  7. Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2018
    Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Michael S SimonDepartment of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA. simonm@karmanos.org.
Pinkal DesaiWeill Cornell Medical College, New York, NY, USA.
Robert WallaceDepartment of Epidemiology, University of Iowa College of Public Health, Iowa City, IA, USA.
Chunyuan WuFred Hutchinson Cancer Research Center, Seattle, WA, USA.
Barbara V HowardMedStar Health Research Institute and Georgetown/Howard Universities Center for Clinical and Translational Sciences, Washington, DC, USA.
Lisa W MartinGeorge Washington University, Washington, DC, USA.
Nicolas SchlechtAlbert Einstein College of Medicine, Bronx, NY, USA.
Simin LiuUCLA School of Public Health, Los Angeles, CA, USA.
Allison JaySt John's Hospital and Medical Center, Detroit, MI, USA.
Erin S LeBlancCenter for Health Research, Kaiser Permanente NW, Portland, OR, USA.
Thomas RohanAlbert Einstein College of Medicine, Bronx, NY, USA.
JoAnn MansonBrigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Funding

Tumor Biology and Microenvironment (Program 1)P30CA022453 · NCI · WAYNE STATE UNIVERSITY · PI PAUL M STEMMER · 1985 to 2026
$68.4M
WOMENS HEALTH INITIATIVE-N01WH22110N01WH022110 · WH · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ROSS, PRENTICE · 1992 to 2006
$1.2M
NCI NIH HHS P30 CA022453NCI NIH HHS P30CA022453WHI NIH HHS N01 WH022110
6 · The paper itself

Abstract

purposeTo determine whether HMG-CoA reductase inhibitors (statins) are associated with a lower risk of pancreatic cancer.

methodsThe population included 160,578 postmenopausal women enrolled in the Women's Health Initiative (WHI) in which 385 incident cases of pancreatic cancer were identified over an average of 8.69 (SD ±4.59) years. All diagnoses were confirmed by medical record and pathology review. Information on statin use and other risk factors was collected at baseline and during follow-up. Multivariable-adjusted hazards ratios (HRs) and 95 % confidence intervals (CIs) evaluating the relationship between prior statin use (at baseline only as well as in a time-dependent manner) and risk of pancreatic cancer were computed from Cox proportional hazards regression analyses after adjusting for appropriate confounders. We also evaluated the effect of statin type, potency, lipophilic status, and duration of use. All statistical tests were two-sided.

resultsStatins were used at baseline by 12,243 (7.5 %) women. The annualized rate of pancreatic cancer in statin users and nonusers, respectively, was 0.0298 versus 0.0271 %. The multivariable-adjusted HR for statin users versus nonusers at baseline was 0.92 and 95 % CI 0.57-1.48. In a time-dependent model, the HR for low-potency statins was 0.46, 95 % CI 0.20-1.04. There was no significant effect seen by statin lipophilicity or duration of use.

conclusionsThere was no significant relationship between statins and pancreatic cancer risk in the WHI; however, there was a marginal inverse association noted for low-potency statins. Analyses of larger numbers of cases are needed to further explore this relationship.

Indexed as

AgedFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMiddle AgedPancreatic NeoplasmsProportional Hazards ModelsProspective StudiesRisk FactorsWomen's HealthHydroxymethylglutaryl-CoA Reductase InhibitorsCancer riskPancreatic cancerStatins

Identifiers

PMID26857832
PMCPMC6849382

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.